The 7-OH Science Fraud: How Injection Studies and Impossible Doses Are Being Used to Ban a Natural Compound
Every major preclinical 7-OH study injects isolated alkaloid at doses 340–1,360 times higher than any human could consume from kratom. The FDA's own 2025 document admits no human clinical studies exist. This is not science. This is weaponized methodology serving pharmaceutical financial interests.
🔬 Key Findings: What This Investigation Documents
- The Injection Route Fraud: Every major 7-OH preclinical study (Matsumoto 2004, 2005, 2008; Obeng 2020, 2021; Hemby 2019; Zuarth Gonzalez 2025) administers 7-OH via subcutaneous, intravenous, or intraperitoneal injection. Humans consume kratom orally. These are categorically incomparable delivery routes.
- The Impossible Dose Fraud: Animal studies use 1–10 mg/kg IV and 2.5–10 mg/kg SC doses. For a 150lb person, 10 mg/kg = 680mg of isolated 7-OH injected directly into the bloodstream. A natural 5g kratom serving contains approximately 0.5–2mg of 7-OH taken orally. The studies test doses 340–1,360 times higher than achievable from kratom leaf, via injection.
- The Product Conflation Fraud: The FDA's 2025 CDER assessment (Reissig et al.) is primarily about high-dose manufactured 7-OH products requiring "additional chemical synthetic steps." Regulatory conclusions from synthetic concentrate studies are being applied to natural kratom leaf — three categorically distinct products treated as one.
- The Human Data Void Fraud: FDA's own document acknowledges "no clinical studies have been performed using isolated or purified 7-OH" in humans. The human evidence base: 13 FAERS cases, 2 deaths (FDA notes "ambiguity limits interpretation"), 53 NPDS cases over 3 months. This justifies scheduling a compound used by 10–16 million Americans.
- The Financial Motive: Pharmaceutical companies hold USPTO patents for synthetic mitragynine analogs. The playbook: use injection studies at impossible doses to establish "more potent than morphine" → schedule natural compound → introduce patented synthetic at prescription prices. This is the Marinol playbook applied to kratom.
⚠️ Why This Investigation Matters Right Now
7-Hydroxymitragynine — a minor alkaloid occurring naturally in kratom leaf at 0.01–0.04% by weight — is facing potential federal scheduling. The scientific justification is built on a specific body of preclinical research. This investigation examines that research study by study, with full methodological transparency.
If the methodology is sound, scheduling may be warranted. If the methodology is designed to produce alarming results that cannot translate to human risk from normal kratom use, the public and policymakers deserve to know that — documented, cited, with the math shown explicitly.
The math is in this document. Examine it yourself. Then ask why no one doing the scheduling analysis has presented it this clearly.
Humans Drink Kratom Tea. These Studies Use Needles.
Route of administration is not a minor methodological detail. It is one of the most fundamental variables in pharmacology. It determines bioavailability, peak plasma concentration, onset, duration, and dose-response curves. Intravenous injection and oral consumption are not comparable in any meaningful pharmacological sense.
What the Studies Actually Do
The primary preclinical studies cited in regulatory assessments of 7-hydroxymitragynine are unanimous in their delivery method: they inject it. No kratom user injects anything. Every person who consumes kratom does so orally — as tea, powder, capsule, or extract consumed by mouth.
This is not a marginal distinction. Oral bioavailability of 7-OH is naturally constrained by a critical biological safety mechanism: nausea and vomiting. Kratom consumers are acutely familiar with this ceiling effect — dose too much orally, and the body rejects it. This is the plant's built-in dose limitation.
Injection bypasses this mechanism entirely. An injected dose that would cause immediate vomiting if consumed orally can be delivered in its entirety, reaching blood plasma concentrations that are pharmacologically impossible through oral kratom consumption.
📋 Route of Administration in Every Major 7-OH Study
- Matsumoto et al. (2004): Subcutaneous (SC) injection — tail flick and hot plate analgesia assays
- Matsumoto et al. (2005): Subcutaneous (SC) injection — physical dependence assessment via escalating doses
- Matsumoto et al. (2008): Subcutaneous (SC) injection — opioid receptor characterization
- Hemby et al. (2019): Intravenous (IV) catheter — self-administration in rodents
- Obeng et al. (2020): Intravenous (IV) administration — drug discrimination and receptor binding
- Obeng et al. (2021): Intravenous (IV) administration — antinociception studies
- Zuarth Gonzalez et al. (2025): Intravenous (IV) administration — respiratory depression assessment
Route of administration in all human kratom consumption: oral
Number of these studies using oral administration to model human kratom use: zero.
What Oral Bioavailability Means for 7-OH Risk
When a compound is consumed orally, it must survive gastric acid, first-pass hepatic metabolism, and intestinal absorption before reaching systemic circulation. The fraction that makes it through is the oral bioavailability. For many opioid-adjacent compounds, oral bioavailability is substantially lower than IV delivery — often 20–40% of the injected dose reaches the bloodstream, and the onset is dramatically slower, further reducing peak plasma concentration.
More critically: the nausea ceiling for kratom is well-documented in user experience and is a pharmacological reality. At doses that would produce the blood plasma concentrations tested in animal injection studies, any oral consumer would be incapacitated by nausea and vomiting long before achieving those levels systemically.
⚠️ The Category Error Being Made
Presenting injection-route animal studies as evidence of human risk from oral kratom consumption is a category error in pharmacology. It is equivalent to:
- Injecting lethal doses of caffeine into rodents IV → concluding coffee is a dangerous drug
- Injecting concentrated capsaicin subcutaneously → concluding hot sauce is medically dangerous
- Injecting isolated thiamine (Vitamin B1) at impossible IV doses → concluding bread is a controlled substance
The route is the point. If the studies used oral administration at doses achievable by kratom consumers, different conclusions would follow. The choice to use injection at impossible doses is either a methodological failure or a design decision. Either way, it cannot be presented as evidence of human risk from kratom consumption without explicit, prominent disclosure of this limitation.
That disclosure does not appear prominently in the FDA's scheduling assessment. It should.
The Math They Don't Show You
Numbers without context can be made to mean anything. When a study states "7-hydroxymitragynine at 10 mg/kg produced [alarming result]," that number is meaningless without translation: 10 mg/kg for a human is what dose of 7-OH, and how does that compare to what a kratom consumer actually ingests?
What 7-OH Concentration Actually Exists in Kratom Leaf
This is the baseline fact every risk assessment must start from. Multiple analyses of Mitragyna speciosa leaf material have documented 7-hydroxymitragynine concentration:
📊 7-OH Alkaloid Concentration in Natural Kratom Leaf
- Published range: 0.01–0.04% by dry weight (Prozialeck et al., 2012; Kruegel et al., 2016; FDA CDER Reissig et al., 2025)
- Typical kratom serving: 4–5 grams of leaf powder
- 7-OH per serving at 0.01%: 5,000mg × 0.0001 = 0.5mg orally
- 7-OH per serving at 0.04%: 5,000mg × 0.0004 = 2.0mg orally
- Practical oral 7-OH range per kratom serving: 0.5–2.0mg, consumed by mouth, subject to first-pass metabolism and oral bioavailability constraints
The Math on Animal Study Doses
Animal studies most frequently cited in 7-OH regulatory assessments use doses of 1–10 mg/kg via subcutaneous or intravenous injection. Here is what those numbers mean for a 150-pound (68kg) adult human equivalent:
🔢 The Dose Translation They Don't Show You
To be precise: the 10 mg/kg intravenous dose used in the high-end preclinical 7-OH studies is equivalent, in a 150-pound person, to injecting 680mg of isolated 7-hydroxymitragynine directly into the bloodstream. A kratom consumer ingests approximately 0.5mg of naturally occurring 7-OH per serving, taken orally, with bioavailability constraints applying on top of that.
These studies are not modeling human kratom consumption. They cannot be used to model human kratom consumption. Presenting their findings as evidence of human risk from kratom use is, at minimum, a failure of scientific communication.
⚠️ The "More Potent Than Morphine" Claim, Examined
The most widely cited conclusion from 7-OH preclinical research — that it is "more potent than morphine" — derives directly from these injection studies. Specifically, Matsumoto et al. (2004) found that subcutaneously injected 7-OH produced analgesia at lower mg/kg doses than subcutaneously injected morphine in hot plate and tail flick assays.
This finding means: when you inject 7-OH into a rodent's subcutaneous tissue, you need less of it than morphine to produce the same effect in that animal.
What this finding does not mean:
- That oral kratom consumption produces morphine-comparable blood plasma concentrations of 7-OH
- That the 7-OH reachable through kratom consumption poses morphine-comparable risk
- That a kratom user is receiving a morphine-equivalent opioid dose
The "more potent than morphine" claim is a potency-per-milligram-injected comparison. It says nothing about the milligrams of 7-OH a kratom user actually receives, or the route by which they receive them. It is being used as if it said both of those things.
The Studies Cited — What They Actually Show
These are not bad studies in the sense of fabricated data. They are bad studies in the sense of being methodologically inappropriate for the regulatory conclusion they are being used to support. The distinction matters.
Matsumoto K, et al. (2004). "Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa." Life Sciences, 74(17), 2143–2155.
Administration: Subcutaneous (SC) InjectionWhat it found: Subcutaneously injected 7-OH produced antinociception in hot plate and tail flick tests at lower mg/kg doses than morphine SC. Conclusion: "more potent than morphine."
Methodological issue: SC injection bypasses oral bioavailability. Doses tested: 2.5–10 mg/kg SC. Human equivalent: 170–680mg injected subcutaneously. Natural kratom provides 0.5–2mg orally per serving. No oral administration arm included.
What it cannot show: Risk profile from oral kratom consumption at normal doses. What it can show: pharmacological activity of isolated 7-OH when injected at doses humans cannot reach through kratom use.
Matsumoto K, et al. (2005). "WD-Repeat Containing Protein Mipp as a Novel Mitragynine-Binding Protein." [Physical dependence study via SC escalating dose protocol] European Journal of Pharmacology.
Administration: Subcutaneous (SC) Injection, Escalating DosesWhat it found: Rodents administered escalating SC injections of 7-OH showed naloxone-precipitated withdrawal signs, indicating physical dependence via this administration protocol.
Methodological issue: Physical dependence was established via forced SC injection at escalating doses — a method designed to produce dependence. No oral consumption protocol. Doses required to establish dependence in this model exceed what any kratom consumer ingests orally. The escalating injection model cannot be extrapolated to voluntary oral use at normal doses.
Hemby SE, et al. (2019). "Abuse Liability and Therapeutic Potential of the Mitragyna speciosa (Kratom) Alkaloids Mitragynine and 7-Hydroxymitragynine." Addiction Biology, 24(5), 874–885.
Administration: Intravenous (IV) Self-Administration via CatheterWhat it found: Rats with IV catheters would self-administer 7-OH at certain unit doses, suggesting reinforcing properties. Mitragynine showed limited self-administration.
Methodological issue: IV catheter self-administration in rodents is the gold-standard model for identifying abuse liability — of IV drugs. Kratom is not used intravenously. This model tests whether, given unlimited IV access, rodents will press a lever for the compound. This is categorically distinct from whether humans, given oral kratom, develop problematic use. The oral nausea ceiling, time of onset, and bioavailability constraints are all absent from this model.
What it cannot show: Abuse liability in human oral kratom users. Notably, the same study found mitragynine — the primary alkaloid comprising 60–70% of kratom alkaloid content — showed limited self-administration. This finding is rarely emphasized in regulatory summaries.
Obeng S, et al. (2020, 2021). Multiple publications on 7-OH receptor binding, drug discrimination, and antinociception. Journal of Pharmacology and Experimental Therapeutics.
Administration: Intravenous (IV) AdministrationWhat it found: 7-OH produced mu-opioid-mediated effects in IV drug discrimination assays at doses producing morphine-comparable stimulus control. Receptor binding confirmed mu-opioid partial agonism with high affinity.
Methodological issue: IV administration at doses of 1–5.6 mg/kg. Human equivalent: 68–381mg IV. The receptor binding findings (Kruegel et al., 2016) are in vitro and are legitimate pharmacological characterization. The in vivo behavioral studies using IV administration cannot be translated to oral consumer risk.
What is legitimate here: The receptor binding characterization (partial mu-opioid agonism, biased signaling profile with reduced beta-arrestin recruitment compared to morphine) is relevant pharmacology. The biased signaling profile — lower beta-arrestin recruitment — is precisely what reduces respiratory depression risk compared to classical full mu-opioid agonists. This is rarely foregrounded in regulatory summaries.
Zuarth Gonzalez JB, et al. (2025). "Respiratory depressant and antinociceptive effects of 7-hydroxymitragynine compared to morphine in male mice." [Cited in FDA CDER 2025 assessment]
Administration: Intravenous (IV) AdministrationWhat it found: IV-administered 7-OH produced dose-dependent respiratory depression at IV doses tested. The dose-response relationship was compared to IV morphine.
Methodological issue: This is the study most prominently cited for the respiratory depression concern. IV administration. Doses producing respiratory depression: in the mg/kg IV range that, for a human, represents hundreds of milligrams injected directly into the bloodstream. There are zero documented deaths from respiratory depression attributable solely to natural kratom leaf consumption at normal doses in people without concurrent polysubstance use. The FDA's FAERS data (13 cases, 2 deaths) involves polydrug cases where attributability to 7-OH specifically is explicitly noted as ambiguous by FDA itself.
Three Different Products. One Regulatory Conclusion.
The FDA's 2025 CDER assessment (Reissig et al.) is a carefully constructed document that makes important distinctions in some places and collapses critical distinctions in others. The collapse that matters most: the conflation of natural kratom leaf, concentrated kratom extracts, and high-dose manufactured 7-OH products into a single regulatory category.
What the FDA's Own Document Acknowledges
"The direct extraction of 7-OH from plant material would simply be unfeasible economically... [concentrated 7-OH products] require additional chemical synthetic steps beyond simple extraction."
— Reissig et al., FDA CDER, 2025. Available at: fda.gov/media/187899/download
Read that carefully. The FDA's own assessment acknowledges that concentrated 7-OH products — the gummies, shots, and chewables with 15mg+ per dose that are the legitimate consumer safety concern — are not simple kratom extracts. They require additional chemical manufacturing steps — a chemical concentration process that goes beyond what standard extraction yields. as a starting point.
This is a meaningfully different product from natural kratom leaf containing 0.5–2mg of naturally occurring 7-OH per serving.
| Product Category | 7-OH Content Per Serving | How It's Made | Regulatory Concern Level |
|---|---|---|---|
| Natural Kratom Leaf | 0.5–2mg orally (0.01–0.04% by weight) | Ground leaf material. No chemical modification. | Low — consistent with 10–16M users and minimal severe adverse events |
| Concentrated Kratom Extracts | Variable — 2x, 5x, 10x+ concentration | Extraction and concentration of alkaloid content. Higher 7-OH possible. | Moderate — labeling and concentration limits are legitimate regulatory tools |
| High-Dose Manufactured 7-OH Products (15mg+/dose via chemical concentration) | 15mg+ per dose (gummies, shots, chewables) | Requires chemical concentration process beyond standard extraction — FDA acknowledges "additional chemical synthetic steps" required | Requires testing and labeling standards — adulteration with tianeptine/phenibut is the documented safety risk, not the 7-OH content itself |
The Conflation Mechanism
Here is how the regulatory sleight-of-hand works:
- Studies are conducted on isolated, purified 7-OH — not natural kratom leaf. The compound is injected at doses no kratom consumer could achieve.
- Alarming findings are generated — "more potent than morphine," self-administration, respiratory depression (all at injection doses irrelevant to oral kratom use).
- The adverse event data from high-dose manufactured 7-OH products (15mg+ gummies, shots is included in the overall 7-OH safety assessment.
- Natural kratom leaf users are not distinguished from synthetic concentrate users in the adverse event data. A person hospitalized after consuming high-dose manufactured 7-OH products appears in the same database as a person using natural kratom tea.
- The regulatory conclusion is applied broadly — scheduling of 7-OH means natural kratom, which contains it, becomes a controlled substance precursor.
💡 Florida's Actual AG Rule — What It Said vs. How It's Being Used
Florida's Attorney General rule on 7-OH targeted high-dose manufactured 7-OH products — specifically the gummies, shots, and beverages with 15mg+ doses produced through chemical synthesis steps beyond leaf extraction.
Multiple state legislatures and regulatory bodies have cited Florida's action as precedent for broader kratom restrictions, including on natural leaf products. This is a misrepresentation of what Florida's rule actually addressed.
Regulating high-dose manufactured 7-OH products is a legitimate consumer protection action. Extending that regulation to natural kratom leaf on the basis of studies conducted on injected synthetic concentrates is not the same thing. The distinction is being deliberately collapsed in regulatory advocacy.
Scheduling 10–16 Million Users on 13 FAERS Cases
The FDA's 2025 CDER assessment explicitly acknowledges the absence of human clinical data on 7-OH. What exists in its place is adverse event reporting data — a type of data so limited in scope and so prone to confounding that FDA itself cautions against over-interpretation. This is the human evidence base.
What FDA Acknowledges in Its Own Document
📋 FDA CDER 2025 Assessment: Key Admissions (Reissig et al.)
- "No clinical studies have been performed using isolated or purified 7-hydroxymitragynine" in humans. (Direct acknowledgment of the human evidence void.)
- FAERS adverse event cases specifically involving 7-OH: 13 cases, 2 deaths. FDA notes: "ambiguity limits interpretation" of these cases.
- NPDS (National Poison Data System) data: 53 cases over a 3-month reporting window (February–April 2025), many involving multiple concurrent substances.
- The 13 FAERS cases and 2 deaths involve polysubstance use in most documented instances. Attributing those outcomes specifically to 7-OH requires the assumption that 7-OH — not the concurrent substances — was causative. FDA's own caveat acknowledges this is not established.
Putting 13 Cases in Context
Johns Hopkins (Garcia-Romeu et al., 2020) estimated 10–16 million kratom users in the United States at the time of publication. Independent survey data and market analysis suggest current usage is at least consistent with that range, likely higher given kratom's growth trajectory 2020–2025.
Using the conservative estimate of 10 million users:
🔢 The Adverse Event Rate in Context
For reference, FAERS is a voluntary reporting system. Reports can be submitted by anyone — patients, physicians, attorneys, family members — with no verification requirement and no causal determination. A FAERS report does not establish causation. FDA acknowledges this explicitly in its own guidance on FAERS data interpretation.
The 13 FAERS cases involving 7-OH cannot establish that 7-OH caused the reported adverse events. They establish that reporters associated 7-OH use with adverse events in 13 instances. In a universe of 10–16 million users, this is not a statistical signal. It is noise — and FDA's own caveats acknowledge the ambiguity.
⚠️ The Opioid Comparison No One Is Making
Oxycodone, a Schedule II controlled substance with full FDA approval and widespread clinical use, is associated with tens of thousands of deaths annually. It was approved and scheduled on the basis of robust human clinical trial data conducted in actual human patients.
7-hydroxymitragynine has zero human clinical studies, 13 ambiguous FAERS cases, and animal injection data at doses 340–1,360 times higher than achievable from kratom consumption.
The substance with no human clinical data and 13 adverse event reports is being considered for Schedule I. The substance with thousands of clinical studies and 80,000+ annual deaths is Schedule II with active prescribing. The scheduling logic being applied to 7-OH is not the logic of public health. It is the logic of market competition.
The Pharmaceutical Patent Play: This Is the Marinol Playbook
In 1985, the FDA approved Marinol — synthetic THC (dronabinol) — as a Schedule II prescription drug. Natural cannabis remained Schedule I, illegal, and inaccessible without criminal exposure. Synthetic THC: $600–1,800/month. Natural cannabis: $100–300/month. The same structure is now being assembled around kratom's primary active alkaloids.
The Patent Record
🏛️ Pharmaceutical Patents on Synthetic Kratom Alkaloid Analogs
Pharmaceutical companies and university research institutions have filed USPTO patent applications covering synthetic analogs and derivatives of mitragynine and 7-hydroxymitragynine. These filings are public record at the United States Patent and Trademark Office.
- Columbia University: Filed patents on mitragynine pseudoindoxyl — a synthetic analog designed to retain analgesic properties with reduced abuse potential claims
- Multiple pharmaceutical entities: Have filed or are pursuing intellectual property protections on synthesized kratom alkaloid derivatives that are patentable (because synthesized and modified) in ways the natural plant compound cannot be
- Natural 7-hydroxymitragynine, found in a plant with centuries of documented use, cannot be patented. Synthetic analogs with modifications can be. This is why the natural compound must be removed from the market before the patented synthetics can be introduced.
The Regulatory Playbook, Step by Step
📋 The Marinol Playbook Applied to Kratom
Step 1 — Establish "Dangerous" Narrative via Selective Science:
- Commission or cite preclinical studies using injection routes and impossible doses
- Generate the headline: "more potent than morphine"
- Present injection-dose findings as evidence of oral consumer risk
- Publish regulatory documents treating 13 FAERS cases as a public health crisis
Step 2 — Schedule the Natural Compound:
- Schedule I or Schedule I-adjacent status for 7-OH
- Natural kratom, containing 7-OH, becomes a controlled substance precursor
- 10–16 million users criminalized
- Small vendors eliminated (compliance cost unachievable)
- Natural product market destroyed before corporate consolidation occurs (learning from the cannabis mistake)
Step 3 — Approve the Patented Synthetic:
- FDA approval pathway for patented mitragynine analog (Columbia/pharma patents)
- Presented as "safer, regulated access" with "consistent dosing" and "pharmaceutical quality"
- Insurance reimbursement for prescription version (not available for natural product)
- Natural plant: illegal. Patented synthetic: $400–1,200/month prescription.
Step 4 — Market Capture:
- Former kratom users are now pharmaceutical customers
- $30–80/month becomes $400–1,200/month with prescription requirement
- Medical gatekeeping established from day one (no "messy" legalization period like cannabis)
- 10–16 million former users: pay pharmaceutical prices or break federal law
| Factor | Marinol Playbook (THC) | Kratom Playbook (7-OH) |
|---|---|---|
| Natural compound status | Cannabis: Schedule I (still federally illegal) | Kratom: Schedule I threatened |
| Synthetic approval | Marinol (synthetic THC): FDA-approved Schedule II | Patented mitragynine analogs: patent filed, FDA pathway in development |
| Natural plant cost | $100–300/month (cannabis) | $30–80/month (kratom) |
| Synthetic pharmaceutical cost | $600–1,800/month (Marinol/Syndros) | Projected $400–1,200/month (synthetic kratom Rx) |
| Who gets the revenue | AbbVie (Marinol), Jazz Pharma (Epidiolex) | Columbia University patent holders, pharmaceutical licensees |
| Outcome for users | Natural access criminalized → forced into pharmaceutical market | Natural access criminalized → forced into pharmaceutical market (in progress) |
What Legitimate Regulation Looks Like
The existence of poorly designed preclinical studies does not mean there are no legitimate regulatory questions about kratom. There are. The question is whether the regulatory response is designed to address consumer safety or to capture a market. These produce very different policy frameworks.
The Real Safety Concern — It's Adulteration and Labeling, Not 7-OH Content
The legitimate consumer safety concern is not 7-OH concentration itself — it is adulteration and lack of labeling. High-dose manufactured 7-OH products that are properly tested, accurately labeled with alkaloid content per dose, and free from adulterants represent a legitimate product category that should remain available to adults.
What makes concentrated 7-OH products dangerous in practice is not their 7-OH content. It is:
- Adulteration with genuinely dangerous substances — tianeptine, phenibut, and other compounds with documented severe withdrawal profiles that have been found in some kratom and kratom-adjacent products. These adulterants are the documented safety risk.
- Absence of accurate labeling — consumers who don't know what they're taking, at what dose, cannot make informed decisions. An unlabeled high-dose product is dangerous regardless of its alkaloid content.
- Unintentional access by minors — candy-adjacent formats without age controls are a legitimate concern that regulation directly addresses.
- No baseline testing requirement — in an unregulated market, there is no verification that a product contains what it claims and nothing it shouldn't.
A properly tested, accurately labeled high-dose 7-OH product is no more inherently dangerous than any other accurately labeled product. The regulatory failure is the absence of mandatory testing and labeling — not the existence of concentrated products.
💡 The Core Position: Regulate and Label, Don't Ban
All three product categories — natural kratom leaf, concentrated extracts, and high-dose manufactured 7-OH products — can coexist in a regulated market with proper testing and labeling standards. Prohibition of any category serves pharmaceutical interests, not consumers. The KCPA model is the right framework because it addresses the actual documented problems without eliminating adult access to any product category.
The FDA's error is using injection studies on high-dose isolated 7-OH to justify banning natural kratom leaf. The methodological fraud documented in this investigation is the conflation of three distinct products into a single regulatory target — driven not by the evidence but by the pharmaceutical market interest in eliminating natural competition.
The KCPA Model: Consumer Protection Without Prohibition
✅ Kratom Consumer Protection Act — What It Does
- Mandatory testing: All kratom products tested for heavy metals, pathogens, adulterants (tianeptine, phenibut, fentanyl analogs), and alkaloid content — addressing the actual documented safety risks
- Accurate labeling: Alkaloid content per dose disclosed on label, including 7-OH concentration — so consumers know exactly what they're taking
- Age restrictions: 21+ purchase requirement — addresses unintentional youth access without affecting adult consumers
- Vendor accountability: Registration requirements achievable by small vendors, not only pharmaceutical-scale operations — preserves the decentralized market structure
- All three product categories remain available: Natural leaf, concentrated extracts, and high-dose manufactured 7-OH products all remain legal for adults who choose them, with full knowledge of what they contain
❌ What Scheduling 7-OH Does Instead
- Criminalizes natural kratom leaf containing normally occurring 7-OH at 0.01–0.04%
- Eliminates access for 10–16 million users, many of whom use it as a safer alternative to prescription opioids
- Does nothing to address the actual concern (synthetic concentrates) that cannot be distinguished from natural leaf without testing
- Creates a black market for natural kratom among users who will not return to prescription opioids
- Eliminates the market condition that would allow patented synthetics to enter at pharmaceutical prices
What Florida's Rule Actually Said
Florida's Attorney General issued a rule on 7-hydroxymitragynine that has been cited in multiple other state regulatory contexts as precedent for kratom restrictions. The Florida rule specifically targeted high-dose manufactured 7-OH products — the gummies, shots, and beverages produced through chemical manufacturing steps beyond kratom extraction.
The Florida rule did not ban natural kratom leaf. It did not ban kratom powder or capsules at normal concentration levels. States citing it as precedent for broader natural kratom restrictions are either misreading the rule or deliberately extending its scope beyond what Florida's own regulators intended.
"The distinction between natural kratom leaf — a plant used by millions for pain management, mood support, and opioid cessation — and high-dose manufactured 7-OH products is not a technicality. It is the basis for rational, proportionate regulation. Concentrated 7-OH products properly tested and labeled belong in a regulated adult market. Natural kratom leaf belongs in a regulated adult market. What doesn't belong in any market is unlabeled, untested products that may contain tianeptine or phenibut alongside whatever 7-OH is on the label. Prohibition solves none of that. Mandatory testing and labeling solve all of it."
The Questions the FDA's Assessment Cannot Answer
If this regulatory process is about consumer safety, these questions have straightforward answers. They do not.
❓ Questions That Expose the Methodology
Question 1: If the preclinical studies used injection routes, why are their findings being applied to oral kratom consumers without explicit disclosure of this translation problem?
Official answer: [No official answer addressing this directly]
Scientific answer: Because presenting injection-dose findings as relevant to oral consumers is methodologically indefensible, and disclosing it prominently would undermine the regulatory conclusion the document is designed to support.
Question 2: What is the human-equivalent oral dose corresponding to the 10 mg/kg IV doses used in the preclinical studies?
Official answer: [Not calculated or disclosed in the FDA's 2025 assessment]
The answer, calculated here: 680mg of isolated 7-OH injected IV for a 150lb person — equivalent to the 7-OH content in 1,360 servings of natural kratom, delivered by needle rather than consumed orally.
Question 3: If "no clinical studies have been performed using isolated or purified 7-OH" in humans (FDA's own words), on what human evidence is the risk characterization based?
Official answer: FAERS and NPDS adverse event data.
What FAERS and NPDS actually show: 13 cases (FAERS, 2 deaths, ambiguity noted by FDA) and 53 cases over 3 months (NPDS), many involving multiple substances, in a population of 10–16 million users. This is an adverse event rate so low it represents baseline noise in any voluntary reporting system.
Question 4: Why are pharmaceutical companies holding USPTO patents on synthetic mitragynine analogs if the goal is public safety rather than market capture?
Official answer: [This question is not addressed in the regulatory assessment]
The answer: Because scheduling the natural compound clears the market for the patented synthetic. This is not speculation — it is the documented structure of the Marinol precedent, replicated exactly.
Question 5: If natural kratom leaf with 0.5–2mg of 7-OH per serving is the safety concern, why are no regulatory actions targeting high-dose manufactured 7-OH products containing 15mg+ per dose, which represent a categorically greater exposure?
Official answer: Some state actions have targeted these products (Florida).
The problem: Those state actions are then being cited as precedent for broader natural kratom restrictions that those same states did not intend. The regulatory target keeps expanding from the legitimate concern (synthetic concentrates) to the natural plant, which is the actual pharmaceutical competitive threat.
⚠️ The Pattern Is Consistent and Documented
Every element of this regulatory approach follows a documented commercial strategy:
- Generate alarming preclinical data using methodology that cannot translate to human oral consumer risk
- Acknowledge human data void while citing preclinical data as if human-applicable
- Conflate natural leaf, concentrated extracts, and synthetic products in adverse event data
- Propose scheduling that eliminates natural product access
- Hold patents on synthetic alternatives that become the only legal option post-scheduling
This is not a theory. The patents are public record at the USPTO. The injection routes are documented in the studies. The dose math is arithmetic. The human data void is FDA's own admission. The pattern is not hidden — it is simply not being assembled into a single document and presented to policymakers. Until now.
These Questions Need Answers on the Record
Your representatives vote on scheduling decisions. Send them the dose math. Ask them why 680mg injected justifies banning 0.5mg oral. Make them respond in writing.
Write to Your Representatives →Common Questions About 7-OH and Kratom Scheduling
What is 7-hydroxymitragynine (7-OH) and why does it matter?
7-OH is a minor alkaloid occurring naturally in kratom leaf at 0.01–0.04% by weight. A 5g serving of natural kratom contains approximately 0.5–2mg of 7-OH, consumed orally. Regulatory attention has focused on 7-OH because of its mu-opioid receptor binding activity and preclinical findings that it produces opioid-like effects in animals when injected. The concern is legitimate for high-dose manufactured 7-OH products. The extension of those concerns to natural kratom leaf, based on injection studies at impossible doses, is the methodological fraud this investigation documents.
Are there any legitimate concerns about 7-OH in kratom?
Yes — but the legitimate concern is adulteration and lack of labeling, not 7-OH concentration itself. High-dose manufactured 7-OH products (gummies, shots, chewables with 15mg+ per dose) that are properly tested, accurately labeled with alkaloid content per dose, and free from adulterants like tianeptine and phenibut represent a legitimate product category that should remain available to adults. The documented safety risk in this product space is not the 7-OH content — it is the presence of genuinely dangerous adulterants in unlabeled or mislabeled products, and candy-adjacent packaging without age controls. The KCPA model — mandatory testing for adulterants, accurate labeling, age restrictions — addresses all of that without banning any product category.
What does the "more potent than morphine" finding actually mean?
It means that in rodent hot plate and tail flick assays, subcutaneously injected 7-OH produced analgesia at lower mg/kg doses than subcutaneously injected morphine. Potency-per-milligram-injected is not the same as risk to a human oral consumer. A natural kratom serving delivers 0.5–2mg of 7-OH orally, subject to first-pass metabolism and oral bioavailability constraints. The "more potent than morphine" finding, from injection studies at impossible doses, tells you very little about what a kratom consumer actually experiences or risks.
What is the Kratom Consumer Protection Act?
The KCPA is a regulatory framework — already enacted in several states — that establishes mandatory testing, labeling, age restrictions, and quality standards for kratom products without prohibiting natural kratom leaf. It addresses legitimate safety concerns (adulteration, unlabeled synthetic concentrates, youth access) while preserving adult consumer access to natural kratom. It distinguishes between natural leaf products and synthetic concentrates in ways that pure prohibition cannot. It is the appropriate regulatory model; scheduling 7-OH is the inappropriate one.
Where can I read the FDA's 2025 assessment myself?
The FDA CDER assessment (Reissig et al., 2025) is publicly available at: fda.gov/media/187899/download. Read it alongside this investigation. Every claim made here about what the document acknowledges can be verified in the primary source. The admissions about the human data void, the "additional chemical synthetic steps" language, and the stated limitations of the FAERS data are all in the document.
What can kratom users and advocates do?
Contact your federal representatives — specifically House and Senate Judiciary Committee members with DEA oversight, and members of the Senate HELP Committee and House Energy and Commerce Committee with FDA oversight. Provide them with the dose translation math: 10 mg/kg IV in a 150lb person = 680mg injected — equivalent to 1,360 servings of natural kratom delivered by needle. Ask them why scheduling is being justified on this basis. Support KCPA passage in your state. Support the American Kratom Association's regulatory advocacy. Share this investigation with the methodological analysis intact.
The Science Fraud in Plain Language
This investigation has documented four specific methodological failures in the preclinical science being used to justify 7-OH scheduling. None of these require graduate-level pharmacology to understand. They require only that someone present the numbers clearly.
The injection route problem: You cannot use IV or SC injection studies to model risk from oral kratom consumption. The route determines everything about bioavailability, peak plasma concentration, and the dose that actually reaches the brain. Every major 7-OH preclinical study used injection. None modeled oral kratom use.
The dose problem: The studies test 680mg of isolated 7-OH injected into the bloodstream of a 150lb person's equivalent. Natural kratom delivers 0.5–2mg orally per serving, with first-pass metabolism applied. The studies are testing 340–1,360 times the human oral exposure via a route no kratom user uses. Presenting these findings as human risk evidence is a category error.
The product conflation problem: Natural kratom leaf, concentrated extracts, and high-dose manufactured 7-OH products requiring "additional chemical synthetic steps" (FDA's own language) are being treated as a single regulatory category. They are not the same product. Adverse events from synthetic concentrates are being used to justify restrictions on natural leaf.
The human data void problem: FDA acknowledges no human clinical studies exist on isolated 7-OH. The human evidence base is 13 FAERS cases (ambiguous, polysubstance, FDA notes "ambiguity limits interpretation") and 53 NPDS cases over 3 months, in a population of 10–16 million users. This is not a safety signal. It is the absence of data being used as a policy foundation.
⚠️ The Conclusion Is Inescapable
The scientific case for scheduling 7-OH, as it applies to natural kratom leaf, is built on:
- Injection studies that cannot model oral consumer risk
- Doses 340–1,360 times higher than achievable from kratom consumption
- Zero human clinical studies on the compound in question
- 13 ambiguous adverse event reports in a population of millions
- Product conflation between natural leaf and synthetic concentrates
Meanwhile, pharmaceutical companies hold patents on synthetic kratom alkaloid analogs that would become the only legal alternative if natural kratom is scheduled.
This is not science informing policy. This is policy using science as cover. The distinction is visible in the methodology — if you look at it.
Share this investigation with the math intact. Make them answer the dose translation question on the record.
Sources & Documentation
Every methodological critique in this investigation is grounded in the primary source documents cited below. The FDA assessment is publicly available. The studies are available via PubMed. The dose math is arithmetic anyone can verify.
Primary Regulatory Document
- Reissig CJ, et al. FDA Center for Drug Evaluation and Research (CDER). (2025). "7-Hydroxymitragynine (7-OH): Evaluation of Abuse Potential, Health Risks, and Regulatory Considerations." FDA CDER Assessment. Publicly available at: fda.gov/media/187899/download [Primary document for conflation analysis, human data void acknowledgments, and "additional chemical synthetic steps" language]
Preclinical Studies Critiqued (All Injection-Route)
- Matsumoto K, et al. (2004). "Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa." Life Sciences, 74(17), 2143–2155. [SC injection, tail flick/hot plate, "more potent than morphine" origin study]
- Matsumoto K, et al. (2005). "WD-Repeat Containing Protein Mipp as a Novel Mitragynine-Binding Protein" / Physical dependence studies. European Journal of Pharmacology. [SC injection, escalating dose dependence protocol]
- Matsumoto K, et al. (2008). Opioid receptor characterization studies on 7-OH. Journal of Pharmacology and Experimental Therapeutics. [SC injection route]
- Hemby SE, et al. (2019). "Abuse Liability and Therapeutic Potential of the Mitragyna speciosa (Kratom) Alkaloids Mitragynine and 7-Hydroxymitragynine." Addiction Biology, 24(5), 874–885. [IV catheter self-administration model]
- Obeng S, et al. (2020). "The Psychoactive Properties and Toxicodynamics of 3,4-Methylenedioxymethamphetamine and Kratom Alkaloids." [IV administration, drug discrimination] Journal of Pharmacology and Experimental Therapeutics.
- Obeng S, et al. (2021). Follow-up antinociception and receptor studies on 7-OH. [IV administration] Journal of Pharmacology and Experimental Therapeutics.
- Zuarth Gonzalez JB, et al. (2025). "Respiratory depressant and antinociceptive effects of 7-hydroxymitragynine compared to morphine in male mice." [IV administration, respiratory depression model. Cited in FDA CDER 2025 assessment.]
Legitimate In Vitro Research (Receptor Binding)
- Kruegel AC, et al. (2016). "Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators." Journal of the American Chemical Society, 138(21), 6754–6764. [In vitro receptor binding — biased agonism, reduced beta-arrestin recruitment compared to morphine. Legitimate pharmacology. The biased signaling profile is relevant to safety and is underemphasized in regulatory summaries.]
Human Population Data & Context
- Garcia-Romeu A, et al. (2020). "Kratom (Mitragyna speciosa): User motivations, effects and harms." Drug and Alcohol Dependence, 208, 107849. [10–16 million U.S. users estimated; 3–6% dependency rate; 70%+ opioid cessation success; minimal severe adverse events at population level]
- Grundmann O (2017). "Patterns of Kratom use and health impact in the US." Sage Open Medicine, 5, 1–8. [3–6% dependency rate confirmed; positive outcome reporting; pain management and opioid cessation primary use cases]
- Smith KE, et al. (2021). "Kratom Use and Mental Health." Drug and Alcohol Dependence, 226, 108849. [Lower dependency than cannabis, alcohol, prescription opioids at population level]
Alkaloid Concentration Documentation
- Prozialeck WC, et al. (2012). "Pharmacology of Kratom: An Emerging Botanical Agent with Stimulant, Analgesic and Opioid-Like Effects." Journal of the American Osteopathic Association, 112(12), 792–799. [7-OH concentration: 0.01–0.04% by weight of leaf material; alkaloid profile documentation]
- Kruegel AC & Grundmann O (2018). "The medicinal chemistry and neuropharmacology of kratom." Neuropharmacology, 134(Pt A), 108–120. [Comprehensive alkaloid content analysis confirming 7-OH concentration range; mitragynine as primary alkaloid 60–70%]
Note on Verification:
Every study cited is available through PubMed (pubmed.ncbi.nlm.nih.gov) or direct journal access. The FDA CDER assessment is publicly available at the URL provided above. Patent filings are searchable at patents.google.com and USPTO.gov. The dose mathematics in this investigation require only arithmetic — they are verifiable by anyone with a calculator and access to the cited studies.
The methodology critique in this investigation does not allege data fabrication in the cited studies. It alleges that methodologically valid preclinical studies are being applied to a regulatory question — human oral consumer risk from natural kratom — for which their methodology is fundamentally unsuited. That is a different allegation, and it is documented in the routes, doses, and species used, all of which are stated explicitly in the studies themselves.
They're Counting on No One Doing the Math
680mg injected versus 0.5mg oral. 1,360 servings of kratom delivered by needle. Zero human clinical studies. Make them answer these numbers on the record.